AZD2115 Multiple Ascending Dose Study

Inclusion Criteria: * Healthy male subjects aged 18 to 45 years with suitable veins for cannulation or repeated venepuncture * Male subjects should be willing to use barrier contraception ie, condoms and spermicide, from the day of first administration of the AZD2115 until 3 months after administration and must not donate sperm for 3 months after follow-up * Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg Exclusion Criteria: * Abnormal vital signs, after 10 minutes supine rest, defined as any of the following: * Systolic BP \>140 mmHg * Diastolic BP \>90 mmHg * Heart rate \<40 or \>85 bpm * Prolonged QTcF \>450 ms or shortened QTcF \<340 ms or family history of long QT syndrome * Serum potassium concentration of \< 3.80 mmol/L on admission (Day -1) * History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with the same class to AZD2115 or to excipients * History or presence of gastrointestinal, pulmonary, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs